MiMedx Group Croissance future
Future contrôle des critères 0/6
Les bénéfices de MiMedx Group devraient diminuer de 4.4% par an tandis que son chiffre d'affaires annuel devrait croître de 1% par an. Le BPA devrait croître de en baisse de 4.1% par an.
Informations clés
-4.4%
Taux de croissance des bénéfices
-4.10%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.6% |
| Taux de croissance des recettes | 1.0% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 30 Apr 2026 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking Alpha
Mise à jour de l'analyse • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Nouvelle analyse • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Mise à jour de l'analyse • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.
Nouvelle analyse • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Mise à jour de l'analyse • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Mise à jour de l'analyse • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Mise à jour de l'analyse • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Mise à jour de l'analyse • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Mise à jour de l'analyse • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Mise à jour de l'analyse • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Article d'analyse • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Article d'analyse • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Article d'analyse • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d'analyse • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Article d'analyse • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Article d'analyse • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Article d'analyse • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d'analyse • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d'analyse • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Article d'analyse • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...
Nouvelle analyse • Sep 24
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.Article d'analyse • May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
MiMedx Group, Inc. ( NASDAQ:MDXG ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Article d'analyse • May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 341 | 26 | 46 | 48 | 2 |
| 12/31/2027 | 317 | 16 | 31 | 46 | 6 |
| 12/31/2026 | 268 | -18 | -2 | 0 | 5 |
| 3/31/2026 | 389 | 31 | 69 | 71 | N/A |
| 12/31/2025 | 419 | 49 | 73 | 74 | N/A |
| 9/30/2025 | 393 | 41 | 67 | 68 | N/A |
| 6/30/2025 | 364 | 32 | 57 | 58 | N/A |
| 3/31/2025 | 352 | 40 | 64 | 66 | N/A |
| 12/31/2024 | 349 | 42 | 65 | 66 | N/A |
| 9/30/2024 | 343 | 79 | 56 | 58 | N/A |
| 6/30/2024 | 340 | 79 | 48 | 51 | N/A |
| 3/31/2024 | 335 | 68 | 34 | 37 | N/A |
| 12/31/2023 | 321 | 56 | 25 | 27 | N/A |
| 9/30/2023 | 309 | 19 | 8 | 11 | N/A |
| 6/30/2023 | 295 | 2 | -4 | -1 | N/A |
| 3/31/2023 | 281 | -18 | -15 | -12 | N/A |
| 12/31/2022 | 268 | -27 | -19 | -18 | N/A |
| 9/30/2022 | 261 | -34 | -17 | -16 | N/A |
| 6/30/2022 | 256 | -28 | -12 | -10 | N/A |
| 3/31/2022 | 258 | -19 | -7 | -6 | N/A |
| 12/31/2021 | 242 | -18 | -5 | -2 | N/A |
| 9/30/2021 | 260 | -35 | -14 | -9 | N/A |
| 6/30/2021 | 261 | -83 | -25 | -20 | N/A |
| 3/31/2021 | 246 | -88 | -30 | -25 | N/A |
| 12/31/2020 | 248 | -83 | -35 | -30 | N/A |
| 9/30/2020 | 256 | -73 | -46 | -43 | N/A |
| 6/30/2020 | 281 | -8 | -44 | -42 | N/A |
| 3/31/2020 | 294 | -17 | -39 | -36 | N/A |
| 12/31/2019 | 299 | -26 | N/A | -39 | N/A |
| 9/30/2019 | 315 | -54 | N/A | -15 | N/A |
| 6/30/2019 | 314 | -67 | N/A | -8 | N/A |
| 3/31/2019 | 342 | -48 | N/A | 10 | N/A |
| 12/31/2018 | 359 | -30 | N/A | 36 | N/A |
| 9/30/2018 | 354 | 41 | N/A | 55 | N/A |
| 6/30/2018 | 352 | 59 | N/A | 70 | N/A |
| 3/31/2018 | 333 | 65 | N/A | 62 | N/A |
| 12/31/2017 | 321 | 65 | N/A | 63 | N/A |
| 9/30/2017 | 303 | 35 | N/A | 59 | N/A |
| 6/30/2017 | 283 | 21 | N/A | 44 | N/A |
| 3/31/2017 | 264 | 15 | N/A | 37 | N/A |
| 12/31/2016 | 222 | 0 | N/A | 24 | N/A |
| 9/30/2016 | 227 | 20 | N/A | 14 | N/A |
| 6/30/2016 | 212 | 23 | N/A | 18 | N/A |
| 3/31/2016 | 200 | 27 | N/A | 14 | N/A |
| 12/31/2015 | 187 | 29 | N/A | 19 | N/A |
| 9/30/2015 | 175 | 20 | N/A | 23 | N/A |
| 6/30/2015 | 160 | 17 | N/A | 24 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Les bénéfices de MDXG devraient diminuer au cours des 3 prochaines années ( -4.4% par an).
Bénéfices vs marché: Les bénéfices de MDXG devraient diminuer au cours des 3 prochaines années ( -4.4% par an).
Croissance élevée des bénéfices: Les bénéfices de MDXG devraient baisser au cours des trois prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de MDXG ( 1% par an) devrait croître plus lentement que le marché de US ( 11.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de MDXG ( 1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MDXG devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/11 12:26 |
| Cours de l'action en fin de journée | 2026/05/08 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
MiMedx Group, Inc. est couverte par 11 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |